About
Antibody Development Platform
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodySingapore
Team (2)
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
4
As Collaborator
1
Total Enrollment
475
By Phase
PHASE1/PHASE2: 3PHASE1: 2
By Status
RECRUITING: 2ACTIVE_NOT_RECRUITING: 2COMPLETED: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
Today
Hover over trial bars to see details
Recent Trials
NCT06956690Lead Sponsor
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
PHASE1/PHASE2Recruiting
180 participants
Started: Oct 31, 2025 · Completed: Jul 31, 2027
NCT05910827Lead Sponsor
Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers, and HMBD-001 + Cetuximab in Advanced Squamous Cell Cancers
PHASE1/PHASE2Recruiting
98 participants
Started: Feb 5, 2024 · Completed: Mar 1, 2026
NCT05919537Lead Sponsor
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
PHASE1Active, not recruiting
68 participants
Started: Sep 6, 2023 · Completed: Mar 1, 2031
NCT05082610Lead Sponsor
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors
PHASE1Completed
48 participants
Started: Feb 28, 2022 · Completed: Dec 3, 2024
NCT05057013Collaborator
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
PHASE1/PHASE2Active, not recruiting
81 participants
Started: Nov 10, 2021 · Completed: Nov 30, 2025
Locations (1)
Headquarters
Singapore, Singapore
Map
Loading map...